Rapport Therapeutics (RAPP) Corporate presentation summary

Leadership and expertise

• Executive team and board have extensive neuroscience, biotech, and pharma experience, including prior leadership at major companies and successful drug development backgrounds.

Precision neuroscience platform and pipeline

• Focus on small molecule precision medicines for neurological and psychiatric disorders, leveraging receptor associated proteins (RAPs) for high selectivity and specificity.

• Lead program RAP-219 targets TARPY8, with robust Phase 2a data in drug-resistant focal onset seizures (FOS) and plans for Phase 3 initiation in Q2 2026.

• Pipeline includes programs for primary generalized tonic-clonic seizures (PGTCS), bipolar mania, chronic pain, migraine, and hearing/vestibular disorders.

RAP-219 clinical data and market opportunity

• RAP-219 demonstrated a 71% reduction in long episodes and 77.8% reduction in clinical seizures in Phase 2a FOS trial, with 85.2% and 72% responder rates, respectively.

• Well tolerated with mostly mild adverse events and a 10% discontinuation rate.

• Addresses large markets: FOS (~$15B), PGTCS (~$7B), and bipolar mania (~$40B), with significant unmet need due to drug resistance and tolerability issues in current therapies.